Reported 2 days ago
Novo Nordisk has laid off dozens of employees at its largest manufacturing site in the U.S. as part of a global restructuring plan, reflecting ongoing shifts under new CEO Mike Doustdar. The job cuts, affecting quality control and production line roles, come amid a strategy to cut 9,000 global positions, as the company seeks to refocus and compete more effectively in the weight loss drug market, particularly against rival Eli Lilly. The layoffs follow prior reductions in U.S. obesity education roles and coincide with unfinished expansion efforts at the Clayton, North Carolina plant.
Source: YAHOO